Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUPH Aurinia Pharmaceuticals	$8.63 -4.9%	$8.15	$5.20 ▼ $10.67	$1.23B	1.16	1.41 million shs	2.01 million shs
CVAC CureVac	$5.39 -0.2%	$4.85	$2.37 ▼ $5.72	$1.21B	2.53	778,558 shs	1.01 million shs
PHVS Pharvaris	$23.25 -2.0%	$17.87	$11.51 ▼ $26.33	$1.24B	-2.82	73,676 shs	24,110 shs
PVLA Palvella Therapeutics	$29.51 -5.5%	$24.05	$7.25 ▼ $31.50	$345.27M	-0.11	146,966 shs	121,435 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUPH Aurinia Pharmaceuticals	-4.85%	-1.93%	+8.96%	+11.18%	+47.77%
CVAC CureVac	-0.19%	-1.28%	-1.82%	+72.76%	+47.67%
PHVS Pharvaris	-2.02%	-7.44%	+39.72%	+66.07%	+26.63%
PVLA Palvella Therapeutics	-5.51%	+11.53%	+43.88%	+21.14%	+2,950,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUPH Aurinia Pharmaceuticals	3.2732 of 5 stars	3.5	2.0	0.0	3.7	0.8	1.9
CVAC CureVac	4.7529 of 5 stars	4.1	5.0	4.9	2.7	0.0	1.3
PHVS Pharvaris	1.3922 of 5 stars	3.5	1.0	0.0	1.9	0.8	0.0
PVLA Palvella Therapeutics	2.9629 of 5 stars	3.6	0.0	0.0	3.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUPH Aurinia Pharmaceuticals	3.00	Buy	$11.50	33.26% Upside
CVAC CureVac	2.20	Hold	$6.83	26.78% Upside
PHVS Pharvaris	3.00	Buy	$36.20	55.70% Upside
PVLA Palvella Therapeutics	3.13	Buy	$46.29	56.85% Upside

Current Analyst Ratings Breakdown

Latest PVLA, AUPH, CVAC, and PHVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	CVAC CureVac	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral	$12.00 ➝ $5.50
6/13/2025	CVAC CureVac	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$7.00 ➝ $5.00
6/12/2025	CVAC CureVac	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform
6/12/2025	CVAC CureVac	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/11/2025	PHVS Pharvaris	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$32.00
6/5/2025	PHVS Pharvaris	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$27.00
5/28/2025	CVAC CureVac	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$10.00
5/16/2025	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$53.00 ➝ $52.00
5/14/2025	PHVS Pharvaris	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$28.00 ➝ $25.00
4/30/2025	CVAC CureVac	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $12.00
4/30/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUPH Aurinia Pharmaceuticals	$235.13M	4.96	$0.29 per share	29.41	$2.68 per share	3.22
CVAC CureVac	$579.18M	2.09	$0.87 per share	6.18	$3.36 per share	1.60
PHVS Pharvaris	N/A	N/A	N/A	N/A	$5.54 per share	N/A
PVLA Palvella Therapeutics	$42.81M	7.62	N/A	N/A	$5.58 per share	5.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUPH Aurinia Pharmaceuticals	$5.75M	$0.28	30.82	15.41	N/A	16.11%	14.27%	9.93%	7/30/2025 (Estimated)
CVAC CureVac	$175.50M	$0.92	5.86	N/A	N/A	35.44%	30.89%	25.54%	8/13/2025 (Estimated)
PHVS Pharvaris	-$145.24M	-$3.01	N/A	N/A	N/A	N/A	-54.02%	-50.36%	8/13/2025 (Estimated)
PVLA Palvella Therapeutics	-$17.43M	-$12.10	N/A	N/A	N/A	N/A	-60.29%	-43.30%	8/13/2025 (Estimated)

Latest PVLA, AUPH, CVAC, and PHVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	CVAC CureVac	-$0.15	N/A	N/A	N/A	$4.27 million	N/A
8/13/2025	Q1 2025	PHVS Pharvaris	-$0.87	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	PVLA Palvella Therapeutics	-$0.81	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	AUPH Aurinia Pharmaceuticals	$0.18	N/A	N/A	N/A	$64.27 million	N/A
5/22/2025	Q1 2025	CVAC CureVac	-$0.16	-$0.24	-$0.08	-$0.24	$4.27 million	$0.94 million
5/15/2025	Q1 2025	PVLA Palvella Therapeutics	-$3.40	-$0.74	+$2.66	-$0.74	N/A	N/A
5/13/2025	Q1 2025	PHVS Pharvaris	-$0.80	-$0.89	-$0.09	-$0.89	N/A	N/A
5/12/2025	Q1 2025	AUPH Aurinia Pharmaceuticals	$0.08	$0.16	+$0.08	$0.16	$61.06 million	$62.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUPH Aurinia Pharmaceuticals	0.16	5.93	5.26
CVAC CureVac	0.05	7.65	7.64
PHVS Pharvaris	N/A	11.10	11.10
PVLA Palvella Therapeutics	N/A	8.84	8.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUPH Aurinia Pharmaceuticals	36.83%
CVAC CureVac	17.26%
PHVS Pharvaris	N/A
PVLA Palvella Therapeutics	40.11%

Insider Ownership

Company	Insider Ownership
AUPH Aurinia Pharmaceuticals	12.20%
CVAC CureVac	2.15%
PHVS Pharvaris	11.84%
PVLA Palvella Therapeutics	20.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUPH Aurinia Pharmaceuticals	300	135.10 million	118.62 million	Optionable
CVAC CureVac	880	224.34 million	219.52 million	Optionable
PHVS Pharvaris	30	52.29 million	46.10 million	Not Optionable
PVLA Palvella Therapeutics	N/A	11.06 million	8.79 million	N/A

PVLA, AUPH, CVAC, and PHVS Headlines

Recent News About These Companies

PVLA - Palvella Therapeutics Inc Sustainability - Morningstar

July 9, 2025 | morningstar.comM

Palvella Therapeutics Completes Enrollment for Pivotal Phase 3 Trial of QTORIN Rapamycin

July 9, 2025 | msn.com

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Buy" by Analysts

July 3, 2025 | marketbeat.com

Palvella Therapeutics, Inc. Added to Russell 3000® and Russell 2000® Indexes as of June 30, 2025

June 30, 2025 | quiverquant.comQ

Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

June 30, 2025 | globenewswire.com

Strid Group LLC Takes $818,000 Position in Palvella Therapeutics, Inc. (NASDAQ:PVLA)

June 29, 2025 | marketbeat.com

PVLA - Palvella Therapeutics Inc Key Metrics - Morningstar

June 27, 2025 | morningstar.comM

PVLA - Palvella Therapeutics Inc Executives - Morningstar

June 26, 2025 | morningstar.comM

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25% | The ...

June 24, 2025 | manilatimes.netM

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by ... - Morningstar

June 24, 2025 | morningstar.comM

Palvella Therapeutics Completes Enrollment for Phase 3 Trial of QTORIN™ Rapamycin in Microcystic Lymphatic Malformations, Anticipates Top-Line Data in 2026 - Nasdaq

June 24, 2025 | nasdaq.com

Palvella Therapeutics Announces Completion of Phase 3 SELVA Trial for QTORIN Rapamycin

June 24, 2025 | msn.com

Palvella Therapeutics Completes Enrollment for Phase 3 Trial of QTORIN™ Rapamycin in Microcystic Lymphatic Malformations, Anticipates Top-Line Data in 2026

June 23, 2025 | quiverquant.comQ

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

June 23, 2025 | globenewswire.com

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

June 18, 2025 | globenewswire.com

Palvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN Rapamycin

June 13, 2025 | msn.com

Palvella Therapeutics Secures FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ for Microcystic Lymphatic Malformations

June 9, 2025 | quiverquant.comQ

Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

June 9, 2025 | globenewswire.com

Palvella Therapeutics Advances in Rare Skin Disease Therapies

May 30, 2025 | tipranks.com

Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

May 27, 2025 | globenewswire.com

Why Palvella Therapeutics, Inc.’s (PVLA) Stock Is Up 5.55%

May 16, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA, AUPH, CVAC, and PHVS Company Descriptions

Aurinia Pharmaceuticals NASDAQ:AUPH

$8.63 -0.44 (-4.85%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$8.82 +0.18 (+2.14%)

As of 07/18/2025 07:07 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

CureVac NASDAQ:CVAC

$5.39 -0.01 (-0.19%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$5.48 +0.10 (+1.76%)

As of 07/18/2025 06:10 PM Eastern

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Pharvaris NASDAQ:PHVS

$23.25 -0.48 (-2.02%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$23.27 +0.02 (+0.09%)

As of 07/18/2025 07:13 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Palvella Therapeutics NASDAQ:PVLA

$29.51 -1.72 (-5.51%)

As of 07/18/2025 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time